Generex Biotechnology Corporation, a company engaged in the research, development, and commercialization of drug delivery systems and technologies, and SciGen, Ltd., a fully integrated biotechnology company globally developing, manufacturing, and marketing biopharmaceuticals, announced April 1, 2008 that they have entered into a distribution agreement for Generex Oral-Lyn™ in China. SciGen will procure governmental approvals for the importation, marketing, distribution, and sale of Generex Oral-Lyn™.

SciGen is a Singapore-based company with offices in the UK and subsidiary companies in South Korea, Inda, Hong Kong, Philippines, Australia, Vietnam, Israel, and the U.S. SciGen’s focus is in the areas of endocrinology, oncology, and immunology. The company’s portfolio includes vaccines and therapeutics.

SciGen will seek governmental approval for the sale of Generex Oral-Lyn™ (pursuant to the terms) in the prescribed territory using SciGen’s own recombinant human insulin product. The Company will supply its recombinant human insulin and Generex will formulate Generex Oral-Lyn™ for marketing and distribution by SciGen in the region.

Let us hear your thoughts below: